BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 19645172)

  • 1. An update on sugammadex sodium.
    Welliver M; Cheek D
    AANA J; 2009 Jun; 77(3):219-28. PubMed ID: 19645172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
    de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
    Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromuscular transmission: new concepts and agents.
    de Boer HD
    J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M
    Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
    Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
    Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacology of sugammadex.
    Bom A; Hope F; Rutherford S; Thomson K
    J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
    Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sugammadex: the first selective binding reversal agent for neuromuscular block.
    Kovac AL
    J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of profound rocuronium or vecuronium-induced neuromuscular block with sugammadex in isoflurane-anaesthetised dogs.
    Mosing M; Auer U; West E; Jones RS; Hunter JM
    Vet J; 2012 Jun; 192(3):467-71. PubMed ID: 22030475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
    Rex C; Bergner UA; Pühringer FK
    Curr Opin Anaesthesiol; 2010 Aug; 23(4):461-5. PubMed ID: 20489603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sugammadex: a novel agent for the reversal of neuromuscular blockade.
    Nicholson WT; Sprung J; Jankowski CJ
    Pharmacotherapy; 2007 Aug; 27(8):1181-8. PubMed ID: 17655516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.
    Plaud B; Meretoja O; Hofmockel R; Raft J; Stoddart PA; van Kuijk JH; Hermens Y; Mirakhur RK
    Anesthesiology; 2009 Feb; 110(2):284-94. PubMed ID: 19194156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
    Ren WH; Jahr JS
    Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sugammadex: a new approach to muscle relaxation and its reversal].
    Duvaldestin P
    Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S39-40. PubMed ID: 19887275
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
    Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
    Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux!
    Lee C; Katz RL
    J Crit Care; 2009 Mar; 24(1):43-9. PubMed ID: 19272538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The concept behind sugammadex.
    Epemolu O; Bom A
    Rev Esp Anestesiol Reanim; 2014 May; 61(5):272-6. PubMed ID: 24636599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007362. PubMed ID: 19821409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sugammadex, a novel drug for neuromuscular blockade reversal].
    Fernández Meré LA; Alvarez-Blanco M
    Rev Esp Anestesiol Reanim; 2010 Feb; 57(2):95-102. PubMed ID: 20337001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.